FULL LENGTH ARTICLE

Downregulation of nc886 contributes to prostate cancer cell invasion and TGFβ1-induced EMT

Ronghui Yang a,1, Lingkun Zuo a,1, Hui Ma a, Ying Zhou a, Ping Zhou b, Liyong Wang a, Miao Wang c, Mahrukh Latif d, Lu Kong a,*

a Department of Biochemistry and Molecular Biology, Capital Medical University, Beijing 100069, PR China
b Biomedical Engineering Institute of Capital Medical University, Capital Medical University, Beijing 100069, PR China
c Department of Pathology, Beijing Friendship Hospital, The Second Clinical Medical College of Capital Medical University, Beijing 100050, PR China
d Department of Nuclear Medicine, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050010, PR China

Received 22 June 2020; received in revised form 9 December 2020; accepted 24 December 2020
Available online 9 February 2021

Abstract  Epithelial-to-mesenchymal transition (EMT) activation is important in cancer progression and metastasis. Evidence indicates that nc886 is a representative Pol III gene that processes microRNA products via Dicer and further downregulates its target gene transforming growth factor-β1 (TGF-β1), which is the most prominent inducer of EMT in prostate cancer (PC). Consistent with the previous literature, we found that nc886 downregulation was strongly associated with metastatic behavior and showed worse outcomes in PC patients. However, little is known about the association between nc886 and the EMT signaling pathway. We developed a PC cell model with stable overexpression of nc886 and found that nc886 changed cellular morphology and drove MET. The underlying mechanism may be related to its promotion of SNAIL protein degradation via ubiquitination, but not to its neighboring genes, TGFβ-induced protein (TGFBI) and SMAD5, which are Pol II-transcribed. TGF-β1 also override nc886 promotion of MET via transient suppression the transcription of nc886, promotion of TGFBI or increase in SMAD5 phosphorylation. Both nc886 inhibition and TGFBI activation occur regardless of their methylation status. The literature suggests that MYC inhibition by TGF-β1 is attributed to nc886 downregulation. We incidentally identified MYC-associated zinc finger
Nc886 inhibits EMT and invasion of prostate cancer cells

Introduction

Prostate cancer (PC) is common in older men. Prostate-specific antigen-based screening is controversial in reducing the mortality of PC. Therefore, the identification of surrogate biomarkers associated with advanced or metastatic PC requires further confirmation.

Current discoveries and advances in the use of ncRNAs as biomarkers have clinical implications in PC. Nc886 (pre-miR-886, CBL3, or VtRNA2-1) was recently identified as a new type of noncoding RNA. The nc886 gene, which is located near a differentially methylated region (DMR) of human chromosome 5, is imprinted and may show allele-specific expression. This gene and its microRNA products (hsa-miR-886-3p and -5p) are often hypermethylated and suppressed in a wide range of cancers, such as cholangiocarcinoma, acute myeloid leukemia (AML), and esophageal, gastric, and lung tumors, and it plays a putative tumor-suppressive role via direct inhibition of protein kinase R. However, levels of nc886 and its microRNA are upregulated in some cancers, including human familial non-medullary thyroid cancer, clear cell renal cell carcinoma, endometrial cancer, high-grade and invasive bladder tumors, and cervical cancer, which suggests an oncogenic role. Therefore, its precise role in cancer requires further confirmation.

Fort et al. suggested that nc886 and its microRNA (also snc886-3p or -5p) processed by Dicer have clinical importance in advanced or metastatic PC, and its expression is silenced by methylation in metastases, which increases cell proliferation and invasive ability. Snc886-3p assists its precursor nc886 in the suppression of tumor growth and invasion in PC primarily due to its target genes, which are associated with cancer cell proliferation and progression. TGF-β1 is a direct target of hsa-miR-886-3p, and it was suppressed at posttranscriptional levels in small cell lung cancer. Our previous transcriptome sequencing data also suggested that nc886 downregulated TGFBI mRNA in highly metastatic PC cell lines. Lee et al. demonstrated that TGF-β induced the expression of nc886, and nc886 emulated TGF-β to promote ovarian cancer progression. These data support a mutual regulation between nc886 and TGF-β1.

TGF-β1 is generally well characterized in PC initiation and progression, and it induces EMT in PC cells. EMT refers to the process by which the expression of mesenchymal markers (such as vimentin and N-cadherin) prevails over epithelial markers (such as E-cadherin) in the balance. EMT transcription factors (EMT-TFs), SNAIL, SLUG, and TWIST downregulate E-cadherin level and change cell plasticity via binding to the E-boxes of the CDH1 promoter in PC. EMT endows cells with migratory and invasive properties to orchestrate the initiation of metastasis. Notably, we observed that stable nc886-overexpressing PC cell lines exhibited epithelial-like characteristics with lower invasive ability in our model. TGF-β1 may be a core signal in linking nc886 with PC. Therefore, the present research elucidates the underlying molecular mechanism of the contribution of nc886 epigenetic silencing to PC invasion and its correlation with the TGF-β-induced EMT pathway, which was rarely reported.

TGFBI (a TGF-β-induced gene) and SMAD5 are effectors in TGF-β-mediated EMT and border nc886. TGFBI-induced EMT accelerates the metastasis of PC. However, early contradictory research suggested that promoter methylation regulates the function of TGFBI as a tumor suppressor in PC and lung cancer. Hypermethylation of the TGFBI promoter is often associated with malignancies. Our bio-informatic analysis revealed that high TGFBI expression was associated with higher PC Gleason grade and negatively correlated with its promoter methylation. However, there was a decrease in PC metastases (Fig. S2). High TGFBI expression indicated a mesenchymal state of tumors, not cancer progression. These data suggest a common epigenetic modification, i.e., methylation, between nc886 and TGFBI. SMAD5 expression in PC positively correlated to TGFBI in our analysis, but negatively correlated to nc886 (Fig. S2). Phosphorylated SMAD1/5 are transcript factors and active mediators in the TGF-β-induced EMT process. Lee et al. showed that TGF-β induced all of the three neighboring genes in the ovary cancer cell line SKOV3, but SMAD5 expression was weaker than TGFBI and nc886. We propose that the three adjacent genes functionally constitute an EMT-synergistic unit regulated by TGF-β, which may play a key role in PC invasion and metastasis. The underlying molecular mechanisms must be elucidated.

Materials and methods

Cell culture and reagents

Human cervical cancer cell lines HeLa and SiHa, the human prostate cancer cell line Du145 and urinary bladder carcinoma (T24) cells were purchased from the Chinese Academy of Science Cell Bank (Shanghai, China). The highly metastatic human PC epithelial cell line PC-3M-1E8 (1E8) and the low metastatic line PC-3M-2B4 (2B4) were obtained from the Peking University Health Science Center (Beijing, China). HeLa, SiHa and Du145 cells exhibit higher nc886 expression.
than in T24, 1E8 and 2B4 cells. Recombinant human TGFβ1 was purchased from PeproTech (96-100-21-10, CT, USA). Cells were incubated in serum-free medium overnight then treated with TGFβ1 for the indicated times. Cells were treated with different concentrations of 5-aza-2′-deoxycytidine (A3656, Sigma) for 5 days and DMSO or Mock as a control by replacing the medium with freshly added drug every 24 h, following the manufacturer’s instructions.

**Chromatin immunoprecipitation (ChIP)**

ChIP experiments were performed following the protocol of the EZ-Magna ChiP assay kit (17–10086, Millipore). One microgram of anti-Pol II was used as a positive control, and the same amount of normal rabbit IgG was used as a negative control. One percent of input and 10% of the immune precipitates were used in PCR analyses using Taq 2 × PCR Master Mix (TQ2201-01, Omega) for 30 cycles at 95°C for 30 s, 58°C for 30 s, and 72°C for 60 s. The primers used for ChIP are listed in the Supplementary Table.

**RNA immunoprecipitation (RIP) assay**

All RIP experiments were performed per the instructions of the RIP-Assay Kit (No. RN1001, MBL, Japan). Anti-DUBA3 (17802-1-AP, Proteintech) or SNAIL antibody (#3879, CST) was used to pull down endogenous nc886 complexes in 1E8 cells (1 × 10⁶ cells). Details are provided in the Supplementary Materials and Methods.

**Oligonucleotide synthesis and plasmid preparation**

The pGLV3-overexpressing nc886 plasmids and negative control plasmids were ordered from Shanghai GenePharma (Shanghai, China). We customized nc886 mimics from Invitrogen (Carlsbad, CA, USA). All sequence information is provided in the Supplementary Table.

Lipofectamine RNAiMax reagent (Invitrogen) was prepared for cell transfection. A total of 1 × 10⁶ cells in a 6-well plate were transfected with 50 nM oligonucleotides or 2 µg of plasmid. To acquire stable nc886-overexpressing 1E8 cell lines, mimic plasmids or control plasmids were transfected and selected in the presence of puromycin (Sigma, Merck Life Science, Shanghai, China).

**Pyrosequencing of the nc886 or TGFBI promoter**

The methylation status of eight CpG islands in the nc886 promoter or 11 CpG islands in the TGFBI promoter was measured using pyrosequencing. Genomic DNA was extracted using a DNA Purification Kit (No. A1120, Promega, USA). One microgram of DNA was used for bisulfite conversion using an Epimet Tect Bisulfite DNA Methylation Kit (No. 59104, QIAGEN, CA, USA). Fifty nanograms of converted DNA were amplified using touchdown PCR. The forward primer was labeled with biotin. Therefore, the PCR products were biotinylated and purified using streptavidin-Sepharose beads (GE Healthcare, USA). After sequencing in the PyroMark ID system (QIAGEN, Germantown, MD, USA), the results were analyzed using PyroMark software (Q24 2.0.6, QIAGEN). Primer sequences are provided in the Supplementary Table. Pyrosequencing assays were repeated 2 times, and the methylation level for each individual CpG site was averaged.

**BALB/c nude mouse bone metastasis model and bone marrow (BM) isolation**

Five-week-old male nude mice (animal ethics number AEEI-2018-067) were used to investigate tumor metastasis. A total of 1 × 10⁵ 1E8 cells with stable nc886 overexpression or control vector were injected into the left ventricle of mice after anesthesia. Each group included at least 10 mice. The animals were sacrificed humanely 4 weeks after tumor cell injection. BM cells were isolated by pelleting and suspended in DMEM containing 10% fetal bovine serum. After overnight culture at 37°C, suspended cells were discarded, and adherent cells were preserved in new DMEM. Cell morphology was photographed under an inverted fluorescence microscope. The tumors were confirmed by histological examination.

**Ubiquitination assay**

Control and mimic cells were lysed in RIPA buffer (P0013B) after incubation with 10 µM MG132 for 6 h. The supernatants were precleared using Protein A/G PLUS-Agarose (sc-2003) at 4°C for 30 min. One milliliter of 300 µg/mL total cellular protein was transferred and added to 1 µg of anti-SNAIL (#3879, CST) at 4°C with rotation for 2 h. Agarose beads (50 µL) were added to the sample and rotated overnight at 4°C. Immunoprecipitants were transferred and washed 4 times with 1 mL of RIPA buffer. After the final washing, 50 µL of loading buffer was pipetted into the sample and boiled for 5 min at 95°C for SDS-PAGE analysis.

**Statistical analysis**

SPSS 19.0 software (Chicago, IL, USA) and GraphPad 5.0 software (San Diego, CA, USA) were used for statistical analyses. Student’s t-test and the nonparametric Spearman rank-correlation test were used in our proposal. All the tests were two-tailed, and statistically significant values were set at P < 0.05. At least three independent datasets were summarized and averaged.

**Results**

**Nc886 is epigenetically suppressed in PC tissues and various cancer cells**

Graded ISH results demonstrated a lower tendency of nc886 expression in high-Gleason (GS, N = 15) and low-GS PC tissues (N = 10) than adjacent normal tissues (N = 5) (Fig. 1A, B). However, no statistical significance was observed due to the small sample size as a limitation. Fort et al (2018) investigated the nc886 TSS200 methylation status in the TCGA-PRAD cohort and showed correlations with tumor metastasis and Gleason grade. This group recently demonstrated that nc886 produced two microRNAs, namely sncc886-3p and -5p, which are processed by DICER, and
snc886-3p was a tumor suppressor in PC cells.\textsuperscript{16} Therefore, we considered the available sn886-3p expression data in public databases as a better proxy for nc886 expression. We observed that metastatic tumors exhibited the lower levels of sn886-3p than primary tumors and normal tissues, as shown in the GSE21032 data (Fig. 1C). nc886 promoter methylation negatively correlated with its expression using Spearman correlation analysis ($P$-value = 0.023, Fig. 5A). Findings from the GSE70770 cohorts also revealed lower levels of snc886-3p in different Gleason groups than benign tissues (Fig. 1D). These data are consistent with the Fort RS report.\textsuperscript{15,16}

Pyrosequencing data also demonstrated that the nc886 DNA hypermethylation was accompanied by low expression in 6 cell lines (Fig. 1E, F, S4B). Sequencing primer information, bisulfite conversion PCR products and detailed methylation information are shown in Figure S1B and Figure S3B. The 2B4 and 1E8 cell lines were treated with the DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-Aza-dC), which effectively induced the re-expression of nc886 in a dose-dependent manner (Fig. 1G). We confirmed that nc886 was suppressed due to CpG DNA hypermethylation in PC tissues and cells, and methylation correlated with cancer progression and metastasis.

**Figure 1** Low nc886 or snc886-3p expression is associated with promoter methylation and PC metastasis event. The expression levels of nc886 were examined using ISH in tissue arrays. (A) A 3'-DIG-labeled nc886 LNA probe, snRNA U6 (positive control), and scramble (negative control) were used. H&E staining suggested PC tissue GS grade (>200). Representative ISH images (>200) from low-GS or high-GS PC tissues showed weaker staining than the adjacent normal tissue. All images were acquired using an Aperio ImageScope system. (B) Statistical graph showing nc886 expression in tissue assays, 5 adjacent normal tissues, 10 low or intermediate GS (<7) tumors, and 10 high-GS (≥8) tumors relative to U6; nonparametric tests. (C, D) Hsa-miR-886-3p (snc886-3p) expression data (log$_2$-normalization) were extracted and analyzed from the publicly available GEO datasets GSE21032 (PC metastasis cohort) and GSE70770 (PC different GS grade cohort). (E) RT-qPCR quality analysis of the nc886 expression in 6 cell lines showing negative expression in 2B4, 1E8 and T24 cells and high expression in HeLa, SiHa and Du145 cells. (F) Quality plot for nc886 average promoter methylation using pyrosequencing showing a total of 8 CpG sites in the 6 cell lines. (G) Expression of nc886 in 1E8 and 2B4 cells stimulated with different concentrations of 5-Aza-dC relative to untreated cells. Two-tailed Student’s $t$-test. $P < 0.05$ indicated a significant difference. The data shown represent the means ± SD of at least 3 independent experiments.
**Nc886 reduces the tumor aggression of PC cells, which is reversed by TGF-β1**

To examine the real function of nc886 in tumor metastasis, we constructed a cell model of nc886 stable overexpression (hereafter referred to as "mimic" or "1E8nc886 b") in a 1E8 cell line with high invasive ability (Fig. 2A). Notably, the mimic changed its cancer cellular morphology and exhibited epithelial characteristics, which consisted of higher expression of E-cadherin or β-catenin and lower expression of N-cadherin, SNAIL or Slug relative to the control group (Fig. 2B), which may be an important mechanism of nc886 promotion of colony formation. The mimic group exhibited increased colony formation (Fig. 2C) but decreased migration and invasive ability (Fig. 2E, F) under nc886 overexpression to an approximately 1000-fold level of the negative control (Fig. 2A). Notably, 10 ng/mL TGF-β1 significantly promoted the invasive ability of control and negative control (Fig. 2A). Notably, 10 ng/mL TGF-β1 significantly promoted the invasive ability of control and negative control (Fig. 2A). Notably, the nc886 overexpression did not affect cell proliferation (Fig. 2D).

In vivo, 1 × 10^5 cancer cells were injected into the left ventricles of BALB/c nude mice to investigate the differences between mimic and control cells in distant metastatic ability after 28 days. We observed a large number of GFP-positive cancer cells from BM aspirates in the control group but not in the mimic group (Fig. 2G). Clearly, nc886 decreased the aggressive ability of tumor cells. However, its mechanism was not clear. Unfortunately, we failed to generate an nc886-KO HeLa or Du145 cell model because of cell growth retardation using CRISPR-Cas9 techniques (Supplementary Materials and Methods), which suggests that nc886 is a lethal gene. Some evidence shows that nc886 silencing activates PKR and induces apoptosis as one such mechanism.29,30

**Nc886 reverses EMT features likely via the promotion of SNAIL ubiquitination**

Nc886, which is transcribed in an antisense direction, is adjacent to two important genes in the EMT signaling pathway. One gene is the TGFBI gene, which is positioned head-to-head and may be a key mesenchymal subtype signature molecule, and the other gene is SMAD5, which has a tail-to-tail position in relation to nc886 (Fig. 3A). We asked whether nc886 promoted MET via TGFBI or SMAD5. Nc886 had no effect on the expression of SMAD5 or TGFBI mRNA or protein using RT-qPCR or Western blot assays, respectively, in mimic cells (Fig. 3B) or nc886-KO HeLa cells (Fig. 3C), which suggests that nc886 did not directly regulate its neighboring genes SMAD5 or TGFBI and that neither TGFBI nor SMAD5 expression was significantly upregulated in the mimic group. Regrettably, nc886-KO HeLa cells failed to proliferate, and Western blot was not performed.

SNAIL protein expression was downregulated approximately 7-fold in mimic cells (Fig. 2B). SNAIL is a suppressive transcription factor for E-cadherin. CDH1 mRNA was upregulated approximately 2-fold in mimic cells (Fig. 3D). Therefore, nc886 may increase the protein level of E-cadherin directly via the downregulation of SNAIL expression. However, SNAIL mRNA showed no changes with 24-h transient or stable overexpression of nc886 (Fig. 3E), which suggests that SNAIL is regulated post-translationally. We observed SNAIL protein re-expression in mimic cells after treatment with the proteasome inhibitor MG132 but not with an inhibitor of autophagy and toll-like receptors (Fig. 3F), chloroquine, which confirmed that SNAIL expression was regulated post-translationally via the ubiquitin-proteasome system (UPS). Nc886 obviously increased the ubiquitination levels of endogenous SNAIL protein (Fig. 3G) in IP experiments after MG132 treatment for 12 h. The SNAIL antibody successfully pulled down the nc886 sequence using PCR detection, but the DUBA3 (a deubiquitinating enzyme) antibody did not pull down the sequence in the subsequent RIP experiment. These results suggest an interaction between nc886 and SNAIL protein (Fig. 3H).

The bioinformatics analysis also suggested that nc886 expression positively correlated with CDH2 and CTNNB1 but negatively correlated with CDH1 and SMAD5 based on GSE70770 data, which is contradictory to the results of the in vitro experiments. This discrepancy may be caused by the inconsistency between mRNA and protein levels or the more complicated EMT in tissue samples. These results require further validation in clinical samples.

**The expression changes of nc886 and its neighboring genes in TGF-β1-induced EMT process**

To confirm that the rescue of TGF-β1-promoted 1E8nc886- cell migration and invasion in Transwell experiments, we examined cell morphological and EMT molecule changes in 1E8nc886- cells compared to controls following TGF-β1 stimulation for 5 days. The results showed that 1E8nc886- and control cells exhibited an elongated fibroblast-like morphology after 5 days (Fig. 4A). Western blot analysis showed a significant reduction in E-cadherin in 1E8nc886- cells and an increase in N-cadherin in the control group after stimulation with 15 or 20 ng/mL TGF-β1 for 5 days (Fig. 4B). These findings indicated that high-concentration and long-term TGF-β1 stimulation sufficiently induced EMT progression and restored mesenchymal characteristics in 1E8nc886- cells. SNAIL was also slightly increased in 1E8nc886- cells after TGF-β1 stimulation, which partially involved the downregulation of E-cadherin in 1E8nc886- cells. We investigated the TGF-β1-induced changes in nc886, TGFBI, SMAD5 and other EMT markers in mimic cell models. Nc886 expression was downregulated, but TGFBI expression was much more upregulated (by 5-fold) in the control group and mimic group following induction by 10 ng/mL TGF-β1 for 2 h, with no observed effect on SMAD5 expression (Fig. 4C, as shown by qRT-PCR). These data were subsequently validated at the protein level using ELISA for TGFBI (Fig. 4D). TGF-β1 temporarily decreased the expression of nc886 in a concentration-dependent manner in mimic cell models (Fig. 4E). We also found that TGF-β1 temporarily and commonly reduced nc886 expression in a time- and concentration-dependent manner for 1 h in nc886-expressing cells (Fig. 4F). TGF-β1 did not induce nc886 expression in nc886-negative cells. Considering the short half-life of nc886 (approximately 75 min), we speculated that TGF-β1 inhibits nc886 expression within a short time. We also observed that TGF-β1 intensely and
persistently activated TGFBI at the mRNA levels in the 6 cell lines (Fig. 4H) and temporarily phosphorylated the SMAD5 protein in a time-dependent manner (Fig. 4G), which was inconsistent with the mRNA level data. These data demonstrate that nc886, TGFBI and SMAD5 are three independent TGF-β1 targets that are inhibited or activated by TGF-β1 in different manners. TGFBI and SMAD5 activation are key events in TGF-β1-promoted EMT in PC cells. However, the differential regulation mechanism for TGF-β1-induced neighboring genes was not elucidated.

Figure 2  Nc886 reverses EMT features and decreases PC cell invasion and metastasis in vitro and in vivo. In vivo, we injected 1 × 10⁶ cancer cells into the left ventricles of BALB/c nude mice to investigate the differences between mimic and control cells in distant metastatic ability after 28 days. (A) Construction of the 1E8 cell model with stable overexpression of nc886. Cells transfected with GFP plasmid were evaluated using real-time PCR and GFP imaging. (B) Comparison of the cell morphology and changes in EMT markers between mimic cell lines and the negative control (N = 3). Statistics plot for Western blots are shown. (C) Colony formation experiments were performed on mimic cell lines, untreated cells or the negative control (N = 6). (D) Stably transfected cells (N = 6) were checked for cell proliferation using the CCK8 assay. (E) Nc886 decreased the wound healing ability of 1E8 cells in scratch assays (N = 6). (F) Transwell invasion was performed using mimic cell lines or the negative control (N = 6) with or without 10 ng/mL TGF-β1 treatment. (G) Representative cell light-microscopy image and statistical plot from a BM aspirate after culturing in DMEM for 1 week showing increased highly heterogeneous cell populations in the control group compared to the mimic. We also detected GFP-positive cancer cells in the control group but not in the mimic group. Error bars represent the SD, and an unpaired t-test (2-tailed) was used. *P < 0.05; **P < 0.01; and ***P < 0.001.
TGF-β1 does not change TGFBI or nc886 promoter methylation levels or the DNMT protein level

Pyrosequencing data confirmed that TGFBI promoter hypermethylation negatively correlated with its expression and caused its expression to be silenced in the 6 cell lines (Fig. 5A, S4A). We verified this result for TGFBI at the protein level using ELISA in the 6 cell lines (Fig. 5B). We found a similar negative correlation between TGFBI promoter hypermethylation and its expression level \( r = -0.149, P = 0.001 \) in the TCGA-PRAD cohort with a clinical T-value \( (N = 490, \text{Fig. } 5C) \). We subsequently measured the changes in the methylation levels of TGFBI and nc886 with TGF-β1 treatment for 24 h in 2B4 and T24 cells, which exhibit low nc886 and TGFBI expression (Fig. 5C, D). Notably, the methylation levels of TGFBI or nc886 in TGF-β1-treated cells were not decreased compared with untreated cells (Fig. 5C, D, S4C). Three active DNA methyltransferases (DNMTs) methylate approximately 70–80% of CpGs in mammals.31 We also found that two DNMT protein levels showed no changes in T24 and 2B4 cells after TGF-β1 treatment at different time-points using Western blotting (Fig. 5E left). Three DNMT protein levels also showed no changes in 1E8nc886+ cells with 10 ng/mL TGF-β1 stimulation for 24 h (Fig. 5E right), which suggests that nc886 is not correlated with DNMTs. These results suggest that promoter methylation levels do not affect changes in nc886 and TGFBI expression. Why promoter...
The expression changes of nc886, TGFBI and SMAD5 after TGF-β1 treatment in PC cells. (A, B) High concentrations of TGF-β1 promote EMT in mimic and control cells. Representative images showing TGF-β1 signal-mediated EMT, and Western blots analyzing changes in known EMT marker (blots and images representative of three independent experiments) in mimic and control cells. (C) RT-qPCR detection of changes in nc886, SMAD5 or TGFBI mRNA after TGF-β1 treatment for 2 h. (D) ELISA was used to examine TGFBI protein activation after TGF-β1 (10 ng/mL) treatment for 24 h. (E) TGF-β1 treatment for 1 h reduced the nc886 expression level in a concentration-dependent manner in mimic cells. (F) TGF-β1 treatment also transiently reduced nc886 levels in a time- or concentration-dependent manner in other nc886-positive cells, such as SiHa, HeLa or Du145 cells. (G) TGF-β1 treatment transiently activated SMAD5 via phosphorylation in the 5-cell line. (H) TGF-β1 treatment for 24 h increased TGFBI level as assessed using RT-qPCR.
hypermethylation did not prevent TGF-β1 stimulation-induced activation of TGFBI at the mRNA level is not known.

**TGF-β1 alters the DNA-binding activity of MAZ within TGFBI promoters**

The GeneCards database revealed a common transcription factor (TF), named MAZ, within the promoters of nc886, TGFBI and CDH1 (Fig. 6A). We examined differences in the DNA-binding activity of Pol II and Pol II-associated MAZ after TGF-β1 treatment using ChIP experiments. Three representative PC cell models were selected: 1E8 cells, for high expression of TGFBI and no expression of nc886; 2B4, for negative expression of nc886 and TGFBI; and Du145, for high expression of TGFBI and nc886. A negative control was performed with IgG, and the positive control used Pol II. Our ChIP PCR detected the binding of MAZ to the TGFBI promoter only in 2B4 cells (red square indicated in Fig. 6B and red tick in Fig. 6C), and MAZ bound to the CDH1 promoter in all three cell lines. MAZ did not bind to the GA box of the first exon region in TGFBI or CDH1. MAZ also did not bind to the A or B promoter region of nc886 (Fig. 6B, C) in any of the three cell lines. TGF-β1 stimulation for 24 h in 2B4 cells decreased the DNA-binding activity of MAZ on the TGFBI promoter for transcription initiation (Fig. 6D), which suggests that TGF-β1 regulates MAZ and serves as a transcriptional suppressor for the TGFBI promoter region in PC cells. However, MAZ does not act as a transcriptional suppressor for the Pol III-transcribed nc886 promoter.

**Discussion**

Our previous findings in vivo established that the core change of nc886 down-regulation of TGF-β1 caused differences in cellular immune rejection in an immunocompetent mouse model. Therefore, we investigated whether TGF-β1-mediated EMT was an important mechanism of nc886 reduction of prostate cancer cell aggressiveness. Our present study demonstrated that the epigenetic silencing of nc886 in metastatic samples better correlated with certain EMT markers, such as CDH1, CDH2 and CTNNB1, in PC. We established a putative association of nc886 and certain EMT molecules with PC progression and EMT change based on clinical data from the GEO analysis shown in Figure S2.
induction. GS ≤ 7 stage PC exhibits primary or locally invasive tumors, which are endowed with more epithelial characteristics, such as increased CDH1 or CDH2, nc886 and CTNNB1 suppression. Cell–cell adhesion is lost at the PC GS/C stage, in which EMT is induced by CDH1 suppression or TGFBI elevation tendencies. Cancer cells with increased invasive properties break down and invade through the basement membrane and enter the bloodstream in a process called intravasation. These circulating tumor cells (CTCs) subsequently exit the bloodstream to form micro-metastases, which suppress nc886, TGFBI or SMAD5. We found that IE8 cell lines with a high invasive ability exhibited nc886 and CDH1 suppression and TGFBI elevation, which are similar to clinical GS/C events (Fig. S2). A good cell model system should reflect in vivo events. We selected the IE8 cell line for an in-depth study of molecular events.

The reintroduction of nc886 to IE8 cells reversed their cell mesenchymal behavior, which consists of the formation of epithelial-like cell clusters and increased colony formation, and decreased cell migration and invasion in vitro and distant bone metastasis in a nude mouse model. However, the reintroduction of TGF-β1 may reverse this benefit. Nc886 is an emerging regulator of MET in PC cells. Therefore, we further examined the mechanism.

We first demonstrated that nc886 failed to alter the expression levels of TGFBI and SMAD5 mRNA and protein, but it promoted SNAIL protein degradation at the post-translational level. RIP experiments established the functional link between nc886 and SNAIL protein in mimic cell lines. The transcription factor SNAIL, which is the first discovered and well known inducer of EMT, suppresses the transcription of E-cadherin via direct binding to its promoter and promotes EMT in cancer metastasis and progression. Most cellular protein degradation is subject to the ubiquitin-proteasome system control. Increasing evidence highlights a role for UPS control in the regulation of SNAIL activity. The present study demonstrated that nc886 significantly reduced the expression of SNAIL partially via its promotion of SNAIL ubiquitination, which may explain the negative correlation of nc886 with CDH1 in PC samples and cells and the further induction of MET occurrence. Nc886 may be a good biomarker for PC metastasis due to its role in EMT fine-tuning of PC cells.

Figure 6 The mechanism of TGF-β1 activation of TGFBI may involve modulation of the ability of MAZ to bind to the TGFBI promoter region. (A) Vein graph showing the common TFs in the CDH1, TGFBI and nc886 promoters from the GeneCards cohort. (B) ChIP experiments investigating MAZ binding to CDH1 promoter, CDH1-GA box, TGFBI-promoter, TGFBI-GA box, nc886 and positive control GAPDH. (C) Summary of the ChIP results for stable expression in three PC cell lines with differential expression of nc886 or TGFBI. √ indicates success in PCR, - indicates failure in PCR, and red highlights the tick. (D) TGF-β1 decreased MAZ binding to TGFBI promoter in 2B4 cells. Representative images are shown from one of three independent experiments.

Nc886 inhibits EMT and invasion of prostate cancer cells
However, TGF-β1 treatment suppresses this function of nc886. TGF-β1, as the direct targets of hsa-miR-886-3p in small cell lung cancer and PC cell lines, was inhibited in mimic cells in our previous study. However, the present study observed that the reintroduction of TGF-β1 temporarily inhibited the transcription of nc886 but activated the transcription of its neighboring gene TGFBI in PC cells, which is consistent with the opposite finding in the advanced ovarian cancer where nc886 has an oncogenic function. Notably, TGF-β1 stimulation did not change the methylation level in the nc886 promoter or TGFBI and DNMT levels, which suggests that the proteins may be regulated via the same epigenetic mechanism. However, their activation mechanisms are diverse in PC cells. It also suggests a differential regulatory mechanism of gene expression for Pol II and neighboring Pol III genes.

One study revealed that TF-MYC induced nc886 elevation, even in a hypermethylated state, in breast cancer cell lines. It is well known that MYC and TGF-β1 are mutually inhibited. We observed that MYC mRNA showed a 1.5-fold increase in mimic cells with a lower TGF-β1 level than the scramble cells using our previous microarray analysis (GSE143451). TGF-β1-induced MYC downregulation may be a mechanism for that the TGF-β1-induced temporary inhibition of nc886. The bioinformatics analysis identified MAZ as a common TF for the promoter regions of nc886, TGFBI and CDH1. MAZ regulates the expression of a variety of genes, for example c-MYC. Notably, MAZ regulates the transcription or termination of two adjacent genes simultaneously because it binds to the transcriptional terminator region of a upstream gene and the promoter region of the following gene. MAZ also binds to the cis-elements in GC-rich promoters in a position-specific manner and may interrupt the elongation of RNA Pol II and stop transcription. We used CDH1 as the control to represent a gene distant from nc886. The ChIP assay clearly revealed that MAZ was a key target of TGF-β1 differential regulation of TGFBI or nc886 expression. Notably, TGF-β1 increased TGFBI mRNA expression via MAZ removal from its promoter, regardless of its methylation status. There is no overlap in promoter regions between nc886 and TGFBI. Although our observation suggests a new mechanism for TGF-β1 differential regulation of the transcription of Pol II and the neighboring Pol III gene, more investigations should be performed in the future. Overall, TGF-β1-induced EMT and nc886-promoted MET in PC cells were not two reversible process. TGFBI activation, SMAD5 phosphorylation, nc886 inhibition and SNAIL overexpression are key events in TGF-β1-induced EMT, but ubiquitinated degradation of SNAIL protein triggered by nc886 are key events in inversely promoting the initiation of MET. SNAIL is commonly regulated by nc886 or TGF-β1, but opposite effects exist (Highlight picture).

In conclusion, our findings reinforce the importance of nc886 in coordinating cell fate, albeit in only 101-nucleotide medium noncoding RNA and Pol III transcripts. The silencing of nc886 in PC leads to increased distant metastatic ability via the EMT pathway. This silencing represents a negative feedback mechanism for precise control of the EMT process in PC. However, this feedback loop is disrupted in a TGF-β1-enriched tumor microenvironment. TGF-β1 transiently inhibits nc886 transcription and rapidly promotes the transcription of TGFBI via modulation of the DNA-binding ability of their common TF (MAZ). Therefore, TGF-β1 “kills two birds with one stone.”

Author contributions

Concept and design: Lu Kong.
Experimental work: Rong-hui Yang and Ling-kun Zuo and Hui Ma and Ying Zhou.
Analysis and interpretation of data (e.g., pathological diagnosis, statistical analysis, biostatistics, computational analysis): Lu Kong, Li-yong Wang, Ping Zhou, Mahrukh Latif and Miao Wang.
Writing and/or revision of the manuscript: Lu Kong and Mahrukh Latif.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflict of interests

Authors have no competing interests to declare.

Acknowledgements

The authors thank Ms. Yang Si for her IHC work and a Mapping Website (BioRender.com) in helping to draw
Nc886 inhibits EMT and invasion of prostate cancer cells

Highlight picture. This work was supported by the Scientific Research Common Program of Beijing Municipal Commission of Education (No. KM202010025004) and the National Nature Science Foundation of China (Nos. 81672834 and 81272406).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.gendis.2020.12.010.

Abbreviations

PC Prostate cancer
ChIP Chromatin immunoprecipitation
MET Mesenchymal-to-epithelial transition
EMT Epithelial-to-mesenchymal transition
DMR Differentially methylated region
ISH in situ hybridization
RIP RNA immunoprecipitation
MAZ MYC associated zinc finger protein
TGFBI Transforming growth factor-beta-induced protein
TGF-β Transforming growth factor-β
DIG Digoxigenin
GS Gleason score
TF Transcription factor

References

1. US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319(18):1901–1913.
2. Song CJ, Chen H, Chen LZ, Ru GM, Guo JJ, Ding QN. The potential of microRNAs as human prostate cancer biomarkers: a meta-analysis of related studies. J Cell Biochem. 2018;119(3):2763–2786.
3. Lee YS. A novel type of non-coding RNA, nc886, implicated in tumor sensing and suppression. Genomics Inform. 2015;13(2):26–30.
4. Romanelli V, Nakabayashi K, Vizoso M, et al. Variable maternal methylation overlapping the nc886/vtRNA2-1 locus is locked between hypermethylated repeats and is frequently altered in cancer. Epigenetics. 2014;9(5):783–790.
5. Kunkeaw N, Jeon SH, Lee K, et al. Cell death/proliferation roles for nc886, a non-coding RNA, in the protein kinase R pathway in cholangiocarcinoma. Oncogene. 2013;32(32):3722–3731.
6. Treppendahl MB, Qui X, Sagar A, et al. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood. 2012;119(1):206–216.
7. Lee HS, Lee K, Jang HJ, et al. Epigenetic silencing of the non-coding RNA nc886 provokes oncogenes during human esophageal tumorigenesis. Oncotarget. 2014;5(11):3472–3481.
8. Cao J, Song Y, Bi N, et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 2013;73(11):3326–3335.
9. Calderon BM, Conn GL. Human noncoding RNA 886 (nc886) adopts two structurally distinct conformers that are functionally opposing regulators of PKR. RNA. 2017;23(4):557–566.
10. Lee EK, Hong SH, Shin S, et al. nc886, a non-coding RNA and suppressor of PKR, exerts an oncogenic function in thyroid cancer. Oncotarget. 2016;7(46):75000–75012.
11. Lei J, Xiao JH, Zhang SH, et al. Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. Mol Med Rep. 2017;16(4):4273–4278.
12. Hu Z, Zhang H, Tang L, Lou M, Geng Y. Silencing nc886, a non-coding RNA, induces apoptosis of human endometrial cancer cells-1A in vitro. Med Sci Monit. 2017;23:1317–1324.
13. Koshnevsiats A, Parvin M, Ghorbanmehr N, et al. A significant upregulation of miR-886-5p in high grade and invasive bladder tumors. Urol J. 2015;12(3):2160–2164.
14. Kong L, Hao Q, Wang Y, Zhou P, Zou B, Zhang YX. Regulation of p53 expression and apoptosis by vault RNA2-1-5p in cervical cancer cells. Oncotarget. 2015;6(29):28371–28388.
15. Fort RS, Matho C, Geraldo MV, et al. Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth. BMC Cancer. 2018;18(1):127.
16. Fort RS, Garat B, Sotelo-Silveira JR, Duhagon MA. vTRNA2-1/nc886 produces a small RNA that contributes to its tumor suppression action through the microRNA pathway in prostate cancer. Noncoding RNA. 2020;6(1):7.
17. Ma H, Wang M, Zhou Y, et al. Noncoding RNA 886 alleviates tumor cellular immunological rejection in host C57BL/C mice. Cancer Med. 2020;9(14):5258–5271.
18. Ahn JH, Lee HS, Lee JS, et al. nc886 is induced by TGF-beta and suppresses the microRNA pathway in ovarian cancer. Nat Commun. 2018;9(1):1166.
19. Cai Q, Chen Y, Zhang D, et al. Loss of epithelial AR increase castration resistant stem-like prostate cancer cells and promotes cancer metastasis via TGF-beta1/EMT pathway. Transl Androl Urol. 2020;9(3):1013–1027.
20. Paolillo M, Schinelli S. Extracellular matrix alterations in metastatic processes. Int J Mol Sci. 2019;20(19):4947.
21. Moradi Monfared M, Alizadeh Zarei M, Rafiei Behbahani A, Arboshgol R, Takhalshi MA. NDRG2 regulates the expression of genes involved in epithelial mesenchymal transition of prostate cancer cells. Iran J Med Sci. 2019;44(2):118–126.
22. Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016;15:18.
23. Singh M, Yelle N, Venugopal C, Singh SK. EMT: mechanisms and therapeutic implications. Pharmacol Ther. 2018;182:80–94.
24. Chen WY, Tsai YC, Yeh HL, et al. Loss of SPDEF and gain of p53 expression and apoptosis by vault RNA2-1-5p in cervical tumors. Mol Med Rep. 2015;12(3):2160–2164.
25. Shah JN, Shao G, Hei TK, Zhao Y. Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. BMC Cancer. 2008;8:284.
26. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005;97(2):103–115.
27. Pan YB, Zhang CH, Wang SQ, et al. Transforming growth factor beta induced (TGFBI) is a potential signature gene for mesenchymal subtype high-grade glioma. J Neurooncol. 2018;137(2):395–407.
28. Ramachandran A, Viz´an P, Das D, et al. TGF-beta uses a novel mode of receptor activation to phosphorylate SMAD1/5 and induce epithelial-to-mesenchymal transition. Elife. 2018;7:e31756.
29. Toth AM, Devaux P, Cattaneo R, Samuel CE. Protein kinase PKR mediates the apoptosis induction and growth restriction phenotypes of C protein-deficient measles virus. J Virol. 2009;83(2):961–968.
30. Lee YS, Kunkeaw N, Lee YS. Protein kinase R and its cellular regulators in cancer: an active player or a surveillance? Wiley Interdiscip Rev RNA. 2020;11(2):e1558.
31. Sharma S, De Carvalho DD, Jeong S, Jones PA, Liang G. Nucleosomes containing methylated DNA stabilize DNA
methyltransferases 3A/3B and ensure faithful epigenetic inheritance. *PloS Genet*. 2011;7(2):e1001286.

32. Meindl-Beinker NM, Dooley S. Transforming growth factor-beta and hepatocyte transdifferentiation in liver fibrogenesis. *J Gastroenterol Hepatol*. 2008;23(Suppl 1):S122–S127.

33. Ji Q, Liu X, Han Z, et al. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-beta1/Smads signaling pathway mediated Snail/E-cadherin expression. *BMC Cancer*. 2015;15:97.

34. Guerriero JL, Sotayo A, Ponichtera HE, et al. Class Ila HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. *Nature*, 2017;543(7645):428–432.

35. Zhu R, Liu Y, Zhou H, et al. Deubiquitinating enzyme PSMD14 promotes tumor metastasis through stabilizing SNAIL in human esophageal squamous cell carcinoma. *Cancer Lett*. 2018;418:125–134.

36. Park JL, Lee YS, Kunkeaw N, Kim SY, Kim IH, Lee YS. Epigenetic regulation of noncoding RNA transcription by mammalian RNA polymerase III. *Epigenomics*. 2017;9(2):171–187.

37. Smith AP, Verrecchia A, Fagà G, et al. A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. *Oncogene*. 2009;28(3):422–430.

38. Medina-Martinez O, Haller M, Rosenfeld JA, O’Neill MA, Lamb DJ, Jamrich M. The transcription factor Maz is essential for normal eye development. *Dis Model Mech*. 2020;13(8):dmm044412.

39. Yu ZH, Lun SM, He R, et al. Dual function of MAZ mediated by FOXF2 in basal-like breast cancer: promotion of proliferation and suppression of progression. *Cancer Lett*. 2017;402:142–152.

40. Álvaro-Blanco J, Urso K, Chiodo Y, et al. MAZ induces MYB expression during the exit from quiescence via the E2F site in the MYB promoter. *Nucleic Acids Res*. 2017;45(17):9960–9975.

41. Kumar P, Yadav VK, Baral A, Kumar P, Saha D, Chowdhury S. Zinc-finger transcription factors are associated with guanine quadruplex motifs in human, chimpanzee, mouse and rat promoters genome-wide. *Nucleic Acids Res*. 2011;39(18):8005–8016.

42. Bossone SA, Asselin C, Patel AJ, Marcu KB. MAZ, a zinc finger protein, binds to c-MYC and C2 gene sequences regulating transcriptional initiation and termination. *Proc Natl Acad Sci U S A*. 1992;89(16):7452–7456.